| 2006 |
ERLIN1 (KE04p) localizes to the ER membrane and is enriched in detergent-insoluble, buoyant (lipid raft-like) fractions in a cholesterol-dependent manner. The extreme N-terminus of ERLIN1 is sufficient for ER targeting in the absence of classical ER retrieval motifs. |
Sucrose gradient fractionation, cholesterol depletion, GFP fusion/heterologous targeting, confocal microscopy |
Journal of cell science |
High |
16835267
|
| 2009 |
ERLIN1 (SPFH1) and ERLIN2 (SPFH2) form a ~2 MDa heteromeric ring-shaped ER membrane complex that binds activated IP3R tetramers prior to their polyubiquitination and is required for IP3R ERAD; RNAi-mediated depletion of SPFH1/2 blocks IP3R polyubiquitination and degradation. |
Native gel/electron microscopy (ring-shaped complex), RNA interference, co-immunoprecipitation, ubiquitination and degradation assays |
The Journal of biological chemistry |
High |
19240031 19751772
|
| 2009 |
The ERLIN1/2 (SPFH1/2) complex associates with activated IP3Rs before polyubiquitination and before p97 recruitment, placing it upstream of ubiquitination in the ERAD cascade; its depletion selectively blocks IP3R ERAD but not IκBα processing or HMG-CoA reductase ERAD. |
RNA interference, co-immunoprecipitation, proteasome inhibitor/pulse-chase degradation assays, calcium mobilization measurement |
Biochimica et biophysica acta |
High |
19751772
|
| 2018 |
ERLIN2 is the dominant subunit in mediating the erlin1/2 complex interaction with IP3Rs; the spastic paraplegia-linked erlin2 T65I mutation dramatically inhibits IP3R interaction and IP3R polyubiquitination/degradation. The erlin1/2 complex selectively binds phosphatidylinositol 3-phosphate (PI(3)P), with erlin2 binding more strongly than erlin1, and the T65I mutation inhibits this PI(3)P binding. |
Gene editing (erlin1 or erlin2 ablation), co-immunoprecipitation, ubiquitination/degradation assays, lipid-binding assays with recombinant proteins, site-directed mutagenesis |
The Journal of biological chemistry |
High |
30135210
|
| 2020 |
ERLIN1 interacts with AMBRA1 at MAM (mitochondria-associated membrane) raft-like microdomains, and this interaction is required for autophagosome formation upon nutrient starvation; the interaction depends on ganglioside GD3 (ST8SIA1) and MFN2 integrity. |
Co-immunoprecipitation, FRET, siRNA knockdown of ERLIN1/ST8SIA1/MFN2, autophagy flux assays (LC3-II, SQSTM1), subcellular fractionation to isolate MAMs |
Autophagy |
Medium |
33034545
|
| 2022 |
The erlin1/2 complex binds to IP3R1 intralumenal loop 3 (IL3), specifically a region close to TM5 (amino acids D2471/R2472); mutation of these residues blocks erlin1/2 complex association. UBE1 inhibition blocks IP3R1 ubiquitination/degradation without altering erlin1/2 complex association, confirming erlin1/2 binding is the primary initiating event preceding ubiquitination. |
Site-directed mutagenesis of IP3R1, co-immunoprecipitation, small-molecule inhibitor (TAK-243) treatment, Ca2+ channel activity assays |
The Journal of biological chemistry |
High |
35568199
|
| 2024 |
The erlin1/2 complex directly and selectively binds PI(3)P; loss or disruption of the complex reduces cellular PI(3)P levels by ~50%, which correlates with decreased autophagic flux without affecting VPS34 kinase activity or the endocytic pathway. |
In vitro PI(3)P binding with recombinant erlins, PI(3)P quantification in cells with E1/E2 KO, autophagic flux assays, VPS34 activity assay, pharmacological PI(3)P depletion |
Biochemical and biophysical research communications |
High |
39018973
|
| 2024 |
ERLIN1/2 scaffolds mediate the interaction between the full-length isoform of TMUB1 and RNF170 via a luminal N-terminal conserved region in TMUB1 and RNF170 that contacts the SPFH domain of adjacent ERLIN subunits. Loss of both ERLINs limits cholesterol esterification, thereby promoting cholesterol transport from ER to Golgi and regulating Golgi morphology and the secretory pathway. |
Co-immunoprecipitation, 3D structural modelling, proteomic (omics) analysis, phenotypic characterization of ERLIN1/2 double-KO HeLa cells, cholesterol transport assays |
Life science alliance |
High |
38782601
|
| 2019 |
ERLIN1 is required for HCV RNA replication and infectious virus production; siRNA silencing of erlin1 reduces intracellular HCV RNA, protein expression, and virus production, with the requirement mapping to a step after cell entry and primary translation but before/during RNA replication. |
siRNA knockdown, HCV infection assays, RNA quantification, protein expression analysis, mechanistic step mapping |
Cells |
Medium |
31810281
|
| 2025 |
Cryo-EM structure of the human erlin1/2 complex reveals a 26-mer cage assembly (13 heterodimers of erlin1 and erlin2), defining a nanometer-sized microdomain on the ER luminal leaflet. Each subunit contains an intramembrane phosphatidylinositol-binding pocket. The complex can cage substrate proteins (e.g., recruiting TMUB1 to interior and exterior of cage), physically secluding them from binding partners; individual cages can cluster to form microdomains of different sizes. |
Single-particle cryo-EM, structural modelling, functional validation of cargo sequestration |
Molecular cell |
High |
41887216
|
| 2025 |
Cryo-EM structures of the ER-resident erlin1/2 complex show it assembles as 13 heterodimers (26-mer), with defined inter-subunit interfaces; key interactions underlying the architecture were described and conformational properties elucidated. |
Single-particle cryo-EM |
bioRxivpreprint |
Medium |
bio_10.1101_2025.04.21.649849
|
| 2025 |
ERLIN1 interacts directly with CYP1A2 via their ER N-terminal signal-anchor domains within detergent-resistant ER membrane microdomains/MAMs; siRNA knockdown of erlin-1 relocates CYP1A2 from DRMs to non-DRMs and impairs its ER-to-lysosomal-associated degradation (ERLAD), resulting in insoluble CYP1A2 aggregates. This ERLAD requirement is rescued by re-expression of erlin-1 or just its N-terminal 1–30 residue signal-anchor domain. |
SURF split-fluorogenic complementation assay (protein-protein interaction), siRNA knockdown, subcellular fractionation (DRM isolation), rescue with siRNA-resistant constructs, CYP2B1 as proof-of-concept |
bioRxivpreprint |
Medium |
bio_10.1101_2025.09.25.678692
|